Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients
Mechanisms underlying biological effects of statin and angiotensin-converting enzyme inhibitor therapies differ. Thus, we studied vascular responses to combination therapy in hypercholesterolemic patients. A randomized, double-blind, placebo-controlled, crossover trial was conducted with 50 hypercho...
Gespeichert in:
| Veröffentlicht in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 2004-08, Vol.44 (2), p.180-185 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 185 |
|---|---|
| container_issue | 2 |
| container_start_page | 180 |
| container_title | Hypertension (Dallas, Tex. 1979) |
| container_volume | 44 |
| creator | Koh, Kwang Kon Son, Ji Won Ahn, Jeong Yeal Kim, Dae Sung Jin, Dong Kyu Kim, Hyung Sik Han, Seung Hwan Seo, Yiel-Hea Chung, Wook-Jin Kang, Woong Chol Shin, Eak Kyun |
| description | Mechanisms underlying biological effects of statin and angiotensin-converting enzyme inhibitor therapies differ. Thus, we studied vascular responses to combination therapy in hypercholesterolemic patients. A randomized, double-blind, placebo-controlled, crossover trial was conducted with 50 hypercholesterolemic patients with simvastatin and either placebo or ramipril (study I) and in 45 hypercholesterolemic diabetic patients with simvastatin or ramipril with placebo or simvastatin combined with ramipril (study II) for 2 months with 2 months washout. In study I simvastatin combined with ramipril significantly reduced blood pressure after 2 months. Simvastatin alone or combined with ramipril significantly changed lipoproteins, improved percent flow-mediated dilator response to hyperemia by 30±5% and 53±6%, respectively (P |
| doi_str_mv | 10.1161/01.HYP.0000133310.42762.25 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66757351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>672340961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5108-4b8ecd823725a45a72d83ae3508369f884c614018dff36df4c7b5588c2e7c8ba3</originalsourceid><addsrcrecordid>eNpdkF1rFDEUhoNY7Fr9CzIU7N1sc_K93sliXaFi0Yp6FTKZDJuamVmTGUv_vafdhQVz85Lkec_HS8g50CWAgksKy82vmyXFA5xzfBZMK7Zk8hlZgGSiFlLx52RBYSXqFcDPU_KylDvEhRD6BTkFCUZwCQvy-Vvs_7oyuSkO1XrsmziEtvoRp2311fVxl2OqbnNwUx-GqUJm87AL2W_HFMoUMkoffXWDdvwvr8hJ51IJrw96Rr5ffbhdb-rrLx8_rd9f114CNbVoTPCtYVwz6YR0mrWGu8AlNVytOmOEVyAomLbruGo74XUjpTGeBe1N4_gZudjX3eXxz4yT2D4WH1JyQxjnYpXSUuN-CJ7_B96Ncx5wNsuoZFpjP4Te7SGfx1Jy6Cyu3bv8YIHax8QtBYuJ22Pi9ilxyySa3xw6zE0f2qP1EDECbw-AK96lLrvBx3LkFAWlQSMn9tz9mDDZ8jvN9yHbbXBp2j61FkyZmqFSg7f6cRjD_wFSuZiv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205277369</pqid></control><display><type>article</type><title>Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Koh, Kwang Kon ; Son, Ji Won ; Ahn, Jeong Yeal ; Kim, Dae Sung ; Jin, Dong Kyu ; Kim, Hyung Sik ; Han, Seung Hwan ; Seo, Yiel-Hea ; Chung, Wook-Jin ; Kang, Woong Chol ; Shin, Eak Kyun</creator><creatorcontrib>Koh, Kwang Kon ; Son, Ji Won ; Ahn, Jeong Yeal ; Kim, Dae Sung ; Jin, Dong Kyu ; Kim, Hyung Sik ; Han, Seung Hwan ; Seo, Yiel-Hea ; Chung, Wook-Jin ; Kang, Woong Chol ; Shin, Eak Kyun</creatorcontrib><description><![CDATA[Mechanisms underlying biological effects of statin and angiotensin-converting enzyme inhibitor therapies differ. Thus, we studied vascular responses to combination therapy in hypercholesterolemic patients. A randomized, double-blind, placebo-controlled, crossover trial was conducted with 50 hypercholesterolemic patients with simvastatin and either placebo or ramipril (study I) and in 45 hypercholesterolemic diabetic patients with simvastatin or ramipril with placebo or simvastatin combined with ramipril (study II) for 2 months with 2 months washout. In study I simvastatin combined with ramipril significantly reduced blood pressure after 2 months. Simvastatin alone or combined with ramipril significantly changed lipoproteins, improved percent flow-mediated dilator response to hyperemia by 30±5% and 53±6%, respectively (P <0.001), and reduced plasma levels of malondialdehyde by 4±7% (P =0.026) and 25±4% (P <0.001), respectively. Monocyte chemoattractant protein-1 levels decreased by 3±3% and 12±2%, respectively (P =0.049 and P <0.001, respectively), C-reactive protein levels changed by 0% and 18%, respectively (P =0.036 and P <0.001, respectively), and plasminogen activator inhibitor-1 antigen levels changed by −7±7% and 17±5%, respectively (P =0.828 and P <0.001, respectively). In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P <0.001 and P =0.048 by ANOVA, respectively). Ramipril alone or simvastatin combined with ramipril significantly improved the percent flow-mediated dilator response to hyperemia (both P <0.001), however, simvastatin combined with ramipril showed significantly more improvement than ramipril alone (P <0.001 by ANOVA). Simvastatin combined with ramipril significantly improved endothelium-dependent vasodilation and fibrinolysis potential and reduced plasma levels of oxidant stress and inflammation markers in hypercholesterolemic patients.]]></description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/01.HYP.0000133310.42762.25</identifier><identifier>PMID: 15184351</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Philadelphia, PA: American Heart Association, Inc</publisher><subject>Angina Pectoris - complications ; Antihypertensive agents ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Biomarkers - metabolism ; Blood and lymphatic vessels ; C-Reactive Protein - metabolism ; Cardiology. Vascular system ; Cardiovascular system ; Chemokine CCL2 - metabolism ; Cholesterol - blood ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Clinical manifestations. Epidemiology. Investigative techniques. Etiology ; Cross-Over Studies ; Diabetes Complications ; Double-Blind Method ; Drug Therapy, Combination ; Endothelium, Vascular - drug effects ; Female ; Humans ; Hypercholesterolemia - complications ; Hypercholesterolemia - drug therapy ; Hypertension - complications ; Male ; Medical sciences ; Middle Aged ; Nitric Oxide - secretion ; Pharmacology. Drug treatments ; Plasminogen Activator Inhibitor 1 - metabolism ; Ramipril - administration & dosage ; Simvastatin - administration & dosage ; Triglycerides - blood ; Vasodilation - drug effects</subject><ispartof>Hypertension (Dallas, Tex. 1979), 2004-08, Vol.44 (2), p.180-185</ispartof><rights>2004 American Heart Association, Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Aug 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5108-4b8ecd823725a45a72d83ae3508369f884c614018dff36df4c7b5588c2e7c8ba3</citedby><cites>FETCH-LOGICAL-c5108-4b8ecd823725a45a72d83ae3508369f884c614018dff36df4c7b5588c2e7c8ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16016717$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15184351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koh, Kwang Kon</creatorcontrib><creatorcontrib>Son, Ji Won</creatorcontrib><creatorcontrib>Ahn, Jeong Yeal</creatorcontrib><creatorcontrib>Kim, Dae Sung</creatorcontrib><creatorcontrib>Jin, Dong Kyu</creatorcontrib><creatorcontrib>Kim, Hyung Sik</creatorcontrib><creatorcontrib>Han, Seung Hwan</creatorcontrib><creatorcontrib>Seo, Yiel-Hea</creatorcontrib><creatorcontrib>Chung, Wook-Jin</creatorcontrib><creatorcontrib>Kang, Woong Chol</creatorcontrib><creatorcontrib>Shin, Eak Kyun</creatorcontrib><title>Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description><![CDATA[Mechanisms underlying biological effects of statin and angiotensin-converting enzyme inhibitor therapies differ. Thus, we studied vascular responses to combination therapy in hypercholesterolemic patients. A randomized, double-blind, placebo-controlled, crossover trial was conducted with 50 hypercholesterolemic patients with simvastatin and either placebo or ramipril (study I) and in 45 hypercholesterolemic diabetic patients with simvastatin or ramipril with placebo or simvastatin combined with ramipril (study II) for 2 months with 2 months washout. In study I simvastatin combined with ramipril significantly reduced blood pressure after 2 months. Simvastatin alone or combined with ramipril significantly changed lipoproteins, improved percent flow-mediated dilator response to hyperemia by 30±5% and 53±6%, respectively (P <0.001), and reduced plasma levels of malondialdehyde by 4±7% (P =0.026) and 25±4% (P <0.001), respectively. Monocyte chemoattractant protein-1 levels decreased by 3±3% and 12±2%, respectively (P =0.049 and P <0.001, respectively), C-reactive protein levels changed by 0% and 18%, respectively (P =0.036 and P <0.001, respectively), and plasminogen activator inhibitor-1 antigen levels changed by −7±7% and 17±5%, respectively (P =0.828 and P <0.001, respectively). In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P <0.001 and P =0.048 by ANOVA, respectively). Ramipril alone or simvastatin combined with ramipril significantly improved the percent flow-mediated dilator response to hyperemia (both P <0.001), however, simvastatin combined with ramipril showed significantly more improvement than ramipril alone (P <0.001 by ANOVA). Simvastatin combined with ramipril significantly improved endothelium-dependent vasodilation and fibrinolysis potential and reduced plasma levels of oxidant stress and inflammation markers in hypercholesterolemic patients.]]></description><subject>Angina Pectoris - complications</subject><subject>Antihypertensive agents</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - metabolism</subject><subject>Blood and lymphatic vessels</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular system</subject><subject>Chemokine CCL2 - metabolism</subject><subject>Cholesterol - blood</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</subject><subject>Cross-Over Studies</subject><subject>Diabetes Complications</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypercholesterolemia - complications</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Hypertension - complications</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nitric Oxide - secretion</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasminogen Activator Inhibitor 1 - metabolism</subject><subject>Ramipril - administration & dosage</subject><subject>Simvastatin - administration & dosage</subject><subject>Triglycerides - blood</subject><subject>Vasodilation - drug effects</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF1rFDEUhoNY7Fr9CzIU7N1sc_K93sliXaFi0Yp6FTKZDJuamVmTGUv_vafdhQVz85Lkec_HS8g50CWAgksKy82vmyXFA5xzfBZMK7Zk8hlZgGSiFlLx52RBYSXqFcDPU_KylDvEhRD6BTkFCUZwCQvy-Vvs_7oyuSkO1XrsmziEtvoRp2311fVxl2OqbnNwUx-GqUJm87AL2W_HFMoUMkoffXWDdvwvr8hJ51IJrw96Rr5ffbhdb-rrLx8_rd9f114CNbVoTPCtYVwz6YR0mrWGu8AlNVytOmOEVyAomLbruGo74XUjpTGeBe1N4_gZudjX3eXxz4yT2D4WH1JyQxjnYpXSUuN-CJ7_B96Ncx5wNsuoZFpjP4Te7SGfx1Jy6Cyu3bv8YIHax8QtBYuJ22Pi9ilxyySa3xw6zE0f2qP1EDECbw-AK96lLrvBx3LkFAWlQSMn9tz9mDDZ8jvN9yHbbXBp2j61FkyZmqFSg7f6cRjD_wFSuZiv</recordid><startdate>200408</startdate><enddate>200408</enddate><creator>Koh, Kwang Kon</creator><creator>Son, Ji Won</creator><creator>Ahn, Jeong Yeal</creator><creator>Kim, Dae Sung</creator><creator>Jin, Dong Kyu</creator><creator>Kim, Hyung Sik</creator><creator>Han, Seung Hwan</creator><creator>Seo, Yiel-Hea</creator><creator>Chung, Wook-Jin</creator><creator>Kang, Woong Chol</creator><creator>Shin, Eak Kyun</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>200408</creationdate><title>Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients</title><author>Koh, Kwang Kon ; Son, Ji Won ; Ahn, Jeong Yeal ; Kim, Dae Sung ; Jin, Dong Kyu ; Kim, Hyung Sik ; Han, Seung Hwan ; Seo, Yiel-Hea ; Chung, Wook-Jin ; Kang, Woong Chol ; Shin, Eak Kyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5108-4b8ecd823725a45a72d83ae3508369f884c614018dff36df4c7b5588c2e7c8ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Angina Pectoris - complications</topic><topic>Antihypertensive agents</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - metabolism</topic><topic>Blood and lymphatic vessels</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular system</topic><topic>Chemokine CCL2 - metabolism</topic><topic>Cholesterol - blood</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</topic><topic>Cross-Over Studies</topic><topic>Diabetes Complications</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypercholesterolemia - complications</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Hypertension - complications</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nitric Oxide - secretion</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasminogen Activator Inhibitor 1 - metabolism</topic><topic>Ramipril - administration & dosage</topic><topic>Simvastatin - administration & dosage</topic><topic>Triglycerides - blood</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koh, Kwang Kon</creatorcontrib><creatorcontrib>Son, Ji Won</creatorcontrib><creatorcontrib>Ahn, Jeong Yeal</creatorcontrib><creatorcontrib>Kim, Dae Sung</creatorcontrib><creatorcontrib>Jin, Dong Kyu</creatorcontrib><creatorcontrib>Kim, Hyung Sik</creatorcontrib><creatorcontrib>Han, Seung Hwan</creatorcontrib><creatorcontrib>Seo, Yiel-Hea</creatorcontrib><creatorcontrib>Chung, Wook-Jin</creatorcontrib><creatorcontrib>Kang, Woong Chol</creatorcontrib><creatorcontrib>Shin, Eak Kyun</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koh, Kwang Kon</au><au>Son, Ji Won</au><au>Ahn, Jeong Yeal</au><au>Kim, Dae Sung</au><au>Jin, Dong Kyu</au><au>Kim, Hyung Sik</au><au>Han, Seung Hwan</au><au>Seo, Yiel-Hea</au><au>Chung, Wook-Jin</au><au>Kang, Woong Chol</au><au>Shin, Eak Kyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>2004-08</date><risdate>2004</risdate><volume>44</volume><issue>2</issue><spage>180</spage><epage>185</epage><pages>180-185</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract><![CDATA[Mechanisms underlying biological effects of statin and angiotensin-converting enzyme inhibitor therapies differ. Thus, we studied vascular responses to combination therapy in hypercholesterolemic patients. A randomized, double-blind, placebo-controlled, crossover trial was conducted with 50 hypercholesterolemic patients with simvastatin and either placebo or ramipril (study I) and in 45 hypercholesterolemic diabetic patients with simvastatin or ramipril with placebo or simvastatin combined with ramipril (study II) for 2 months with 2 months washout. In study I simvastatin combined with ramipril significantly reduced blood pressure after 2 months. Simvastatin alone or combined with ramipril significantly changed lipoproteins, improved percent flow-mediated dilator response to hyperemia by 30±5% and 53±6%, respectively (P <0.001), and reduced plasma levels of malondialdehyde by 4±7% (P =0.026) and 25±4% (P <0.001), respectively. Monocyte chemoattractant protein-1 levels decreased by 3±3% and 12±2%, respectively (P =0.049 and P <0.001, respectively), C-reactive protein levels changed by 0% and 18%, respectively (P =0.036 and P <0.001, respectively), and plasminogen activator inhibitor-1 antigen levels changed by −7±7% and 17±5%, respectively (P =0.828 and P <0.001, respectively). In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P <0.001 and P =0.048 by ANOVA, respectively). Ramipril alone or simvastatin combined with ramipril significantly improved the percent flow-mediated dilator response to hyperemia (both P <0.001), however, simvastatin combined with ramipril showed significantly more improvement than ramipril alone (P <0.001 by ANOVA). Simvastatin combined with ramipril significantly improved endothelium-dependent vasodilation and fibrinolysis potential and reduced plasma levels of oxidant stress and inflammation markers in hypercholesterolemic patients.]]></abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>15184351</pmid><doi>10.1161/01.HYP.0000133310.42762.25</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0194-911X |
| ispartof | Hypertension (Dallas, Tex. 1979), 2004-08, Vol.44 (2), p.180-185 |
| issn | 0194-911X 1524-4563 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66757351 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Angina Pectoris - complications Antihypertensive agents Arterial hypertension. Arterial hypotension Biological and medical sciences Biomarkers - metabolism Blood and lymphatic vessels C-Reactive Protein - metabolism Cardiology. Vascular system Cardiovascular system Chemokine CCL2 - metabolism Cholesterol - blood Cholesterol, HDL - blood Cholesterol, LDL - blood Clinical manifestations. Epidemiology. Investigative techniques. Etiology Cross-Over Studies Diabetes Complications Double-Blind Method Drug Therapy, Combination Endothelium, Vascular - drug effects Female Humans Hypercholesterolemia - complications Hypercholesterolemia - drug therapy Hypertension - complications Male Medical sciences Middle Aged Nitric Oxide - secretion Pharmacology. Drug treatments Plasminogen Activator Inhibitor 1 - metabolism Ramipril - administration & dosage Simvastatin - administration & dosage Triglycerides - blood Vasodilation - drug effects |
| title | Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A48%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Simvastatin%20Combined%20With%20Ramipril%20Treatment%20in%20Hypercholesterolemic%20Patients&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Koh,%20Kwang%20Kon&rft.date=2004-08&rft.volume=44&rft.issue=2&rft.spage=180&rft.epage=185&rft.pages=180-185&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/01.HYP.0000133310.42762.25&rft_dat=%3Cproquest_cross%3E672340961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=205277369&rft_id=info:pmid/15184351&rfr_iscdi=true |